<SEC-DOCUMENT>0001070081-21-000035.txt : 20211028
<SEC-HEADER>0001070081-21-000035.hdr.sgml : 20211028
<ACCEPTANCE-DATETIME>20211028160258
ACCESSION NUMBER:		0001070081-21-000035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211028
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211028
DATE AS OF CHANGE:		20211028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		211358189

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ptct-20211028x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/28/2021 7:58:52 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 1d012265-7ba7-467d-9865-85514f505896 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20211028" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityCentralIndexKey" id="Tc_6y7UpqkCF02x21GcGBJ10Q_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:AmendmentFlag" id="Tc_Ph0ZH-iQeEyaqrHLrH7Ysw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20211028.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-28</xbrli:startDate><xbrli:endDate>2021-10-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1c2b8121_8120_4d2c_bf9a_3bd62a26e6df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:DocumentType" id="Narr_YixKN8_uF0i4OMbtNOLWCw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_xvqAwwFfK02qYi2AblWT_A"><b style="font-size:9pt;font-weight:bold;">October 28, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityRegistrantName" id="Narr_9YavHJbpAE-vWnZRlvVJfQ"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_liQSYOy4P0-UUVqTz89DFg_2_0"></a><a id="Tc_4zIRWjqLok2SJuPSMMhAZw_2_2"></a><a id="Tc_nq_5HcfpJ0Sz9LjC_ePLHA_2_4"></a><a id="Tc_sNQGnpqmDkW-sgia_3vzDQ_3_0"></a><a id="Tc_9lBL-3PTo0aHhYoRNeYOCA_3_2"></a><a id="Tc_a-QkSwSoQ0SGuNYEaeAKQg_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_sDsBr8UoCUypzz9KU4XC5Q_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityFileNumber" id="Tc_ViXkFhHkHEunBN_Qp04wmQ_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityTaxIdentificationNumber" id="Tc_Uab-wYMSOUGZ1x1hZXh4Qw_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_B8-r9hNDO0mmZdwzdnE3tA_2_0"></a><a id="Tc_AlnU5p8zDkGgQjcO8UQKBg_3_0"></a><a id="Tc_0zeAo_3Z5EOgNkQiqgTHmw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityAddressAddressLine1" id="Tc_2I3YOsu_Fk292F4WpZ3Sag_1_0"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityAddressCityOrTown" id="Narr_QhW0NBy5LkOREe7mNJmKaw"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityAddressStateOrProvince" id="Narr_Uvxj20NVkkqDwVH6ZmSukw"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:EntityAddressPostalZipCode" id="Tc_Lllr8RaK4EWjjyVMVjd8RA_2_2"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.53%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:CityAreaCode" id="Narr_7s08p0K1skq0Hk5cN7wE7A"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:LocalPhoneNumber" id="Narr_A49I7Nx8l0KS4MLO9WSldw"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_GelM5wQuWE-329eThAhShg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_dtJCVijhoUCtw9gg4xBQ-w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_7ojsDC7dC0uj-weYswNtmg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_8XjRNoRkFkq8eJYTcM_zAg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_jFZ7b_r_b0-9Xz61YD0fWg_1_0"></a><a id="Tc_rQVsN4sVgUC-mQ8vYFduPg_1_2"></a><a id="Tc_3crTpyG_NEO5vF8p6LpKWw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:Security12bTitle" id="Tc_5By9SucPgEW7yX0bJIe4TQ_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" name="dei:TradingSymbol" id="Tc_D6CoK4y21EWB5_657CVgQg_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_7FHcYnJmvUeWTqztBVxvUw_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_DaVNRNafS0GYNVzNiyyNOw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_19297151_79a8_496d_8004_b29eb9c0053b"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Item 2.02. Results of Operations and Financial Condition.</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">On October 28, 2021, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this &quot;Report&quot;) and is incorporated by reference into this Item 2.02.</p><a id="_e91e6d67_1879_459f_b93d_e7469c1f2937"></a><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7.01.&#160;Regulation FD Disclosure.</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company will host a conference call on October 28, 2021 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended September 30, 2021, as well as other corporate highlights and updates.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00c374eb_0118_4061_8a8d_70ded480bd97"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="ptct-20211028ex9914df365.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press Release, dated October 28, 2021 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_63e2b05b_6c05_4329_ae5b_8f5aebdbaf1a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 28, 2021</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Emily Hill</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emily Hill</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ptct-20211028ex9914df365.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 10/28/2021 07:58:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:15.0pt;margin-right:9pt;width:84.3pt;z-index:251658240;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:84.3pt;"><img src="ptct-20211028ex9914df365001.jpg" alt="Logo&#10;&#10;Description automatically generated" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides a Corporate Update and <br>Reports Third Quarter 2021 Financial Results<br></b><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';">&#160; </font><font style="font-family:'Arial','Helvetica','sans-serif';">- Total quarterly revenue of $139 million; 17% increase over third quarter 2020 -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="background-color:#ffffff;color:#333333;font-family:'Arial','Helvetica','sans-serif';">- Raises </font><font style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';">2021 DMD franchise revenue guidance </font><font style="font-family:'Arial','Helvetica','sans-serif';">to $400-$420M from $370-$390M - </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- Continues to advance robust clinical pipeline by initiating a fifth registration-directed trial, APHENITY Phase 3 trial of PTC923 in phenylketonuria (PKU) &#8211;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">- Brazil achievements include Category 1 pricing for Tegsedi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';">, regulatory approval of Waylivra&#8482; and expansion of the Translarna&#8482; label to include patients as young as 2 years of age -</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">SOUTH PLAINFIELD, N.J., Oct 28, 2021</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2021.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><font style="background-color:#ffffff;color:#242424;font-family:'Arial','Helvetica','sans-serif';">The stellar growth of our DMD franchise is remarkable.</font><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221; said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;</font><font style="background-color:#ffffff;color:#242424;font-family:'Arial','Helvetica','sans-serif';">I continue to be impressed by the team&#8217;s performance. The commercial performance, along with the milestones achieved in Brazil, and the continued advancements in our pipeline, with initiating a fifth registration-directed trial, allows us continued value creation for all of our stakeholders.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Third Quarter and Other Corporate Updates:</b></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">The Duchenne muscular dystrophy (DMD) franchise grew 39% over the third quarter of 2020, demonstrating PTC&#8217;s continued strong commercial performance. Quarterly net product revenue for the franchise was $114 million in the third quarter of 2021. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Translarna&#8482; (ataluren) revenue growth was driven by geographic expansion and new patient identification.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (deflazacort) revenue growth was driven primarily by new patient starts and maintained high compliance. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Evrysdi&#8482;(risdiplam) continues to show strong global uptake. The first commercial sale of Evrysdi&#8482; in Japan occurred in August 2021, resulting in a $10 million milestone payment from Roche to PTC with $325 million in sales-based milestones remaining. Evrysdi&#8482; is a product of a collaboration between PTC, Roche and the SMA Foundation.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Waylivra&#8482; (volanesorsen) was approved by the Brazilian Health Regulatory Agency, ANVISA (Ag&#234;ncia Nacional de Vigil&#226;ncia Sanit&#225;ria), as the first treatment for familial chylomicronemia syndrome (FCS) in Brazil.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Times New Roman';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Tegsedi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (inotersen) has successfully received Category 1 classification from CMED (Drug Market Regulation Chamber) in Brazil. Category 1 classification is given to innovative treatments that provide greater efficacy than current standards of care and allows for pricing in line with international markets.</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="background-color:#ffff00;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Third Quarter Clinical Updates:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The APHENITY registration-directed Phase 3 trial for PTC923 for phenylketonuria (PKU) has been initiated with results expected by the end of 2022.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">PTC continues to make progress in three additional ongoing registration-directed clinical studies: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The MIT-E Phase 2/3 vatiquinone trial for mitochondrial disease associated seizures with results anticipated in the third quarter of 2022. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The MOVE-FA Phase 3 vatiquinone trial for Friedreich ataxia with results anticipated in 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Enrollment in the FITE19 Phase 2/3 emvododstat trial in patients with COVID-19 is expected to be completed by year end 2021. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The Phase 1 healthy volunteer study of PTC518 for Huntington&#8217;s disease met the objectives in the third quarter of this year. The Phase 2 study in patients with Huntington&#8217;s disease is expected to be initiated by the end of 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">The Committee for Medicinal Products for Human Use (CHMP) opinion on the PTC-AADC gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency is expected in the fourth quarter of 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">For the Biologics License Application (BLA) for AADC deficiency, PTC expects to submit the BLA in the first quarter of 2022.</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;"><a name="_Hlk70065754"></a></font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Third Quarter 2021 Financial Highlights:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Total revenues were $138.7 million for the third quarter of 2021, compared to total revenues of $118.4 million for the third quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Total revenue includes net product revenue across the commercial portfolio of $115.6 million and royalty and collaboration revenue of $23.1 million for the third quarter of 2021, compared to net product revenues of $82.7 million and royalty and collaboration revenues of $35.7 million for the third quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Translarna net product revenues were $67.2 million for the third quarter of 2021, compared to $43.4 million for the third quarter of 2020. These results reflect an increase in net product sales in existing markets as well as continued geographic expansion.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Emflaza net product revenues were $47.1 million for the third quarter of 2021, compared to $38.5 million for the third quarter of 2020. These results reflect new patient prescriptions, high compliance, and fewer discontinuations.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Roche reported Evrysdi 2021 year to date sales of approximately CHF 396 million, resulting in year-to-date royalty revenue of $33.3 million to PTC. During the third quarter of 2021, the first commercial sale of Evrysdi in Japan triggered a $10 million milestone payment from Roche to PTC, which was reported as collaboration revenue.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">U.S. GAAP (generally accepted accounting principles) research and development (R&amp;D) expenses were $130.8 million for the third quarter of 2021, compared to $93.0 million for the third quarter of 2020. The increase reflects additional investment in research programs and advancement of the clinical pipeline.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Non-GAAP R&amp;D expenses were $117.8 million for the third quarter of 2021, excluding $13.0 million in non-cash stock-based compensation expense, compared to $83.8 million for the third quarter of 2020, excluding $9.2 million in non-cash stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">GAAP selling, general and administrative (SG&amp;A) expenses were $69.3 million for the third quarter of 2021, compared to $57.8 million for the third quarter of 2020. The increase reflects our continued investment to support commercial activities including expanding our commercial portfolio.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Non-GAAP SG&amp;A expenses were $56.4 million for the third quarter of 2021, excluding $12.8 million in non-cash stock-based compensation expense, compared to $50.3 million for the third quarter of 2020, excluding $7.6 million in non-cash stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Change in the fair value of deferred and contingent consideration was $10.8 million for the third quarter of 2021, compared to $8.4 million for the third quarter of 2020. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC&#8217;s acquisition of Agilis, which closed in August 2018.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Net loss was $133.6 million for the third quarter of 2021, compared to net loss of $69.7 million for the third quarter of 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Cash, cash equivalents and marketable securities was $867.9 million at September 30, 2021, compared to $1.1 billion at December 31, 2020.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">Shares issued and outstanding as of September 30, 2021 were 70,665,010.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Updates Full Year 2021 Guidance as Follows:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">PTC now anticipates net product revenues for the DMD franchise for the full year 2021 to be between $400 and $420 million from previous guidance of $370 and $390 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">PTC now anticipates GAAP R&amp;D and SG&amp;A expense for the full year 2021 to be between $815 and $835 million from previous guidance of $825 and $855 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:left;">PTC now anticipates Non-GAAP R&amp;D and SG&amp;A expense for the full year 2021 to be between $715 and $735 million, excluding estimated non-cash, stock-based compensation expense of $100 million, from previous guidance of $725 and $755 million.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results and financial guidance of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial statements by providing greater transparency into the historical and projected operating performance of PTC and the Company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the tables below.</font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Segoe UI';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.23;text-align:center;margin:0pt 0pt 8pt 4.5pt;"><a name="Section1"></a><font style="font-size:10pt;line-height:1.28;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 53pt 0pt 60.5pt;">PTC Therapeutics, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0.4pt 53pt 8pt 60.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.4pt 52.8pt 0pt 60.5pt;"><font style="font-family:'Times New Roman','Times','serif';">(In thousands, except share and per share data)</font></p><div style="padding-left:0.35pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:104.74%;"><tr style="height:9.05pt;"><td colspan="6" style="vertical-align:top;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:7.7pt;text-align:right;margin:0pt 4.05pt 0pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:22.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:7.7pt;margin:0pt 0pt 0pt -1.9pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Nine Months Ended September 30,</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr style="height:11pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8.5pt;margin:1.5pt 0pt 0pt 10.8pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8.5pt;margin:1.5pt 0pt 0pt 7.85pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8.5pt;margin:1.5pt 0pt 0pt 7.95pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:8.5pt;margin:1.5pt 0pt 0pt 10.4pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:14.75pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:2.15pt 0pt 0pt 10pt;">Revenues:</p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:13.7pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.64pt 0pt 0pt 16.7pt;">Net product revenue</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">115,605</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 2.95pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="white-space:pre-wrap;">82,708       </font></p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.15pt 2.3pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0.64pt 0pt 0pt 2.8pt;">$</p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">309,998</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.15pt 2.3pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 0.1pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">226,143</p></td></tr><tr style="height:14.2pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.1pt 0pt 0pt 16.7pt;">Collaboration revenue</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">10,011</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">35,000</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">30,018</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">35,063</p></td></tr><tr style="height:13.2pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.1pt;margin:1.14pt 0pt 0pt 16.7pt;">Royalty revenue</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">13,127</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">696</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">33,348</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:11.1pt;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">696</p></td></tr><tr style="height:13.25pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.1pt;margin:2.15pt 0pt 0pt 10pt;">Total revenues</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">138,743</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">118,404</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">373,364</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">261,902</p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.1pt;margin:2.15pt 0pt 0pt 10pt;">Operating expenses:</p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:14.8pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.15pt 0pt 0pt 13.6pt;">Cost of product sales</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">6,539</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">4,667</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">23,001</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">14,056</p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.39pt 0pt 0pt 14.05pt;">Amortization of acquired intangible asset</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">14,383</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">9,630</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">38,411</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">26,309</p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.14pt 0pt 0pt 14.05pt;">Research and development (1)</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">130,845</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">92,998</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">390,840</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">359,630</p></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.14pt 0pt 0pt 14.05pt;">Selling, general and administrative (2)</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">69,252</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">57,840</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">199,225</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">169,708</p></td></tr><tr style="height:23.5pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.99;margin:2.75pt 61.1pt 0pt 13.95pt;">Change in the fair value of deferred and contingent consideration</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="white-space:pre-wrap;">      10,800</font></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">8,400</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">11,600</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">16,980</p></td></tr><tr style="height:12.85pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.1pt;margin:0.8pt 0pt 0pt 13.6pt;">Settlement of deferred and contingent</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">-</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">-</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">-</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">10,613</p></td></tr><tr style="height:13.25pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10.1pt;margin:2.15pt 0pt 0pt 10pt;">Total operating expenses</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">231,819</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">173,535</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">663,077</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">597,296</p></td></tr><tr style="height:14.75pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:2.15pt 0pt 0pt 10pt;">Loss from operations</p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(93,076)</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(55,131)</p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(289,713)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(335,394)</p></td></tr><tr style="height:13.7pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.64pt 0pt 0pt 10pt;">Interest expense, net</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(21,802)</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:1.45pt 4.4pt 0pt -0.75pt;">(21,039)</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:1.45pt 4.4pt 0pt -0.75pt;">(63,520)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(32,060)</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.1pt;margin:1.1pt 0pt 0pt 10pt;">Other (expense) income, net</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(18,782)</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">28,766</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(26,499)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">26,242</p></td></tr><tr style="height:14.75pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:2.15pt 0pt 0pt 10pt;">Loss before income tax expense</p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(133,660)</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(47,404)</p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(379,732)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(341,212)</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0.64pt 0pt 0pt 10pt;">Income tax benefit (expense)</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">36</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(22,288)</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(904)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(22,594)</p></td></tr><tr style="height:15.2pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:2.15pt 0pt 0pt 10pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(133,624)</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(69,692)</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(380,636)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(363,806)</p></td></tr><tr style="height:25.15pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 10pt;">Weighted-average shares outstanding:</p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.1pt 0pt 0pt 16.7pt;">Basic and diluted (in shares)</p></td><td colspan="2" style="vertical-align:top;width:11.46%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:1.45pt 2.75pt 0pt 0pt;"><font style="white-space:pre-wrap;">     70,585,938</font></p></td><td colspan="3" style="vertical-align:top;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:1.45pt 2.75pt 0pt 0pt;"><font style="white-space:pre-wrap;">         67,641,171</font></p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:1.1pt -7.95pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:1.45pt 2.75pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 70,397,846</font></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:1.45pt 2.75pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 65,068,281</font></p></td></tr><tr style="height:14.15pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.99;margin:2.2pt 16.95pt 0pt 10pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(1.89)</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(1.03) </p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(5.41)</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.64pt 4.4pt 0pt -0.75pt;"><font style="font-size:9pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0.64pt 4.4pt 0pt -0.75pt;">$</p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0.64pt 4.4pt 0pt -0.75pt;">(5.59)</p></td></tr><tr style="height:34.15pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 10pt;"><b style="font-weight:bold;">(1) Research and development reconciliation</b></p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.2pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:7.09pt 0pt 0pt 10pt;">GAAP research and development</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:7.09pt 1.6pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">130,845</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:7.09pt 2.95pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">92,998</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:7.09pt 0pt 0pt 2.8pt;">$</p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">390,840</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:7.09pt 0.1pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">359,630</p></td></tr><tr style="height:26.65pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:7.15pt 0pt 0pt 10pt;">Less: share-based compensation expense</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">13,048</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">9,220</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">40,216</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">25,961</p></td></tr><tr style="height:20.9pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6.25pt 0pt 0pt 10pt;"><b style="font-weight:bold;">Non-GAAP research and development</b></p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:6.25pt 1.6pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">117,797</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:6.25pt 0pt 0pt 2.8pt;">$</p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">83,778</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:6.25pt 0pt 0pt 2.8pt;">$</p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">350,624</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:6.25pt 0.1pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">333,669</p></td></tr><tr style="height:51.6pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.97;margin:0pt 61.6pt 0pt 10pt;"><b style="font-weight:bold;">(2) Selling, general and administrative reconciliation</b></p></td><td style="vertical-align:top;width:1.9%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.98%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:23.85pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:4.75pt 0pt 0pt 10pt;">GAAP selling, general and administrative</p></td><td style="vertical-align:top;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">69,252</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">57,840</p></td><td style="vertical-align:top;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">199,225</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">169,708</p></td></tr><tr style="height:21pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:7.15pt 0pt 0pt 10pt;">Less: share-based compensation expense</p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">12,823</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">7,559</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">37,061</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt -0.75pt;">22,948</p></td></tr><tr style="height:16.4pt;"><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6.34pt 0pt 0pt 10pt;"><b style="font-weight:bold;">Non-GAAP selling, general and administrative</b></p></td><td style="vertical-align:top;width:1.9%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:6.34pt 1.6pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.55%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">56,429</p></td><td style="vertical-align:top;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.75%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:9.55pt 2.35pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:8.19%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">50,281</p></td><td style="vertical-align:top;width:0.98%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 2.8pt;">$</p></td><td style="vertical-align:top;width:9.88%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt 0pt;">162,164</p></td><td style="vertical-align:top;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:9.55pt 2.35pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.27%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:9.55pt 2.35pt 0pt 0pt;">$</p></td><td style="vertical-align:top;width:9.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:9.55pt 2.35pt 0pt -0.75pt;">146,760</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0.4pt 52.8pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:-0pt 53pt 0pt 60.5pt;">PTC Therapeutics, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0.34pt 53.1pt 8pt 60.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary Consolidated Balance Sheets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.4pt 52.9pt 0pt 60.5pt;"><font style="font-family:'Times New Roman','Times','serif';">(in thousands, except share data)</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12.5pt;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:5.85pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:105.36%;"><tr style="height:12.2pt;"><td colspan="3" style="vertical-align:top;width:81.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-align:right;margin:0pt 6.1pt 0pt 0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td colspan="2" style="vertical-align:top;width:18.55%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt 0pt 0pt 6.4pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr style="height:14pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.69pt 0pt 0pt 10pt;">Cash, cash equivalents and marketable securities</p></td><td style="vertical-align:top;width:5.36%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.69pt 0pt 0pt 2.65pt;">$</p></td><td style="vertical-align:top;width:13.8%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.69pt 0pt 0pt 26.35pt;">867,943</p></td><td style="vertical-align:top;width:5.42%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.69pt 0pt 0pt 4.6pt;">$</p></td><td style="vertical-align:top;width:13.13%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.69pt 7.1pt 0pt 0pt;">1,103,650</p></td></tr><tr style="height:15.9pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.69pt 0pt 0pt 10pt;"><b style="font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:top;width:5.36%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:2.65pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:13.8%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:6.5pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">2,007,325</b></p></div></td><td style="vertical-align:top;width:5.42%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:4.6pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:13.13%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:4.6pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">2,208,278</b></p></div></td></tr><tr style="height:26.65pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 10pt;">Total debt</p></td><td style="vertical-align:top;width:5.36%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-top:0.55pt;padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 2.65pt;">$</p></td><td style="vertical-align:top;width:13.8%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-top:0.55pt;padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 26.35pt;">430,962</p></td><td style="vertical-align:top;width:5.42%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-top:0.55pt;padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 4.6pt;">$</p></td><td style="vertical-align:top;width:13.13%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-top:0.55pt;padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 7.05pt 0pt 0pt;">309,145</p></td></tr><tr style="height:15pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.5pt 0pt 0pt 10pt;">Total liability for sale of future royalties</p></td><td style="vertical-align:top;width:5.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.5pt 0pt 0pt 26.35pt;">723,200</p></td><td style="vertical-align:top;width:5.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:1.5pt 4.55pt 0pt 0pt;">679,762</p></td></tr><tr style="height:15.4pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.5pt 0pt 0pt 10pt;">Total deferred revenue</p></td><td style="vertical-align:top;width:5.36%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.8%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:1.5pt 4.3pt 0pt 0pt;">-</p></td><td style="vertical-align:top;width:5.42%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:1.5pt 4.4pt 0pt 0pt;">4,151</p></td></tr><tr style="height:15.9pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.69pt 0pt 0pt 10pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:top;width:5.36%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:2.65pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:13.8%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:18.9pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1,902,399</b></p></div></td><td style="vertical-align:top;width:5.42%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:4.6pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:13.13%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:7.1pt;margin-top:0.69pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">1,726,296</b></p></div></td></tr><tr style="height:44.35pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.99;text-align:justify;margin:0pt 13.15pt 0pt 10pt;">Total stockholders&#39; equity (70,665,010 and 69,718,096 common shares issued and outstanding at September 30, 2021 and December 31, 2020 respectively)</p></td><td style="vertical-align:top;width:5.36%;border-bottom:1.0pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:9.19pt 0pt 0pt 2.65pt;">$</p></td><td style="vertical-align:top;width:13.8%;border-bottom:1.0pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:9.19pt 0pt 0pt 26.35pt;">104,926</p></td><td style="vertical-align:top;width:5.42%;border-bottom:1.0pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:9.19pt 0pt 0pt 4.6pt;">$</p></td><td style="vertical-align:top;width:13.13%;border-bottom:1.0pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt;"><div style="padding-top:3.0px;border-top:1.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:9.19pt 7.05pt 0pt 0pt;">481,982</p></td></tr><tr style="height:15.9pt;"><td style="vertical-align:top;width:62.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.6pt 0pt 0pt 10pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#39; equity</b></p></td><td style="vertical-align:top;width:5.36%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:2.65pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:13.8%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:6.5pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">2,007,325</b></p></div></td><td style="vertical-align:top;width:5.42%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:4.6pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:13.13%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:4.6pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">2,208,278</b></p></div></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0.1pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:15pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 53pt 0pt 60.5pt;">PTC Therapeutics, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0.4pt 53.15pt 8pt 60.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2021 R&amp;D and SG&amp;A Expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.4pt 52.9pt 0pt 60.5pt;"><font style="font-family:'Times New Roman','Times','serif';">(In thousands)</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0.2pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:2.5pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:6.55pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:105.1%;"><tr style="height:12.2pt;"><td colspan="4" style="vertical-align:top;width:80.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;text-align:right;margin:0pt 5.85pt 0pt 0pt;">Low End of Range</p></td><td colspan="3" style="vertical-align:top;width:19.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt 0pt 0pt 8.6pt;">High End of Range</p></td></tr><tr style="height:13.8pt;"><td style="vertical-align:top;width:61.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.6pt 0pt 0pt 10pt;">Projected GAAP R&amp;D and SG&amp;A Expense</p></td><td style="vertical-align:top;width:1.19%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.69%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.6pt 0pt 0pt 2.7pt;">$</p></td><td style="vertical-align:top;width:12.23%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.6pt 7.3pt 0pt 0pt;">815,000</p></td><td style="vertical-align:top;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.66%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.6pt 0pt 0pt 2.6pt;">$</p></td><td style="vertical-align:top;width:12.25%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.6pt 7.35pt 0pt 0pt;">835,000</p></td></tr><tr style="height:15.15pt;"><td style="vertical-align:top;width:61.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:1.25pt 0pt 0pt 10pt;">Less: projected non-cash, stock-based compensation expense</p></td><td style="vertical-align:top;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.69%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.23%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:1.25pt 7.15pt 0pt 0pt;">100,000</p></td><td style="vertical-align:top;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.25%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:1.25pt 7.25pt 0pt 0pt;">100,000</p></td></tr><tr style="height:15.9pt;"><td style="vertical-align:top;width:61.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.6pt 0pt 0pt 10pt;"><b style="font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense</b></p></td><td style="vertical-align:top;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.69%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:2.7pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:12.23%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:7.3pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">715,000</b></p></div></td><td style="vertical-align:top;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.66%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-left:2.6pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">$</b></p></div></td><td style="vertical-align:top;width:12.25%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><div style="margin-right:7.35pt;margin-top:0.6pt;padding-bottom:3.0px;border-bottom:1.5pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">735,000</b></p></div></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:3.5pt 53pt 0pt 60.5pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#8217;s Conference Call and Webcast Reminder: &#160;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC will host a conference call to discuss the third quarter of 2021 corporate updates and financial results today at 4:30 pm ET and can be access by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 7064479. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Kylie O&#8217;Keefe</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 300-0691</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">kokeefe@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Updates Full Year 2021 Guidance as Follows&quot;, including with respect to (i) 2021 net product revenue guidance and (ii) 2021 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters; expectations with respect to PTC&#39;s gene therapy platform, including any regulatory submissions and manufacturing capabilities; advancement of PTC&#39;s joint collaboration program in SMA, including the commercialization of </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">any products therein or royalty or milestone payments; PTC&#39;s expectations with respect to the licensing, regulatory submissions and commercialization of its other products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: expectations with respect to the COVID-19 pandemic and related response measures and their effects on PTC&#39;s business, operations, clinical trials, regulatory submissions and approvals, and PTC&#39;s collaborators, contract research organizations, suppliers and manufacturers; the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC&#39;s gene therapy platform, including any regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of ongoing studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any regulatory submissions and commercialization with respect to Evrysdi; PTC&#39;s ability to utilize results from Study 041 to support a marketing approval for Translarna for the treatment of nmDMD in the United States; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC&#39;s ability to fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi&#8482; and Waylivra&#8482;; the enrollment, conduct and results of PTC&#39;s clinical trial for emvododstat for COVID-19; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; PTC&#39;s ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Evrysdi, Tegsedi, Waylivra or PTC-AADC.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.<br></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ptct-20211028ex9914df365001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ptct-20211028ex9914df365001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "= 0(# 2(  A$! Q$!_\0
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M^HZ&OG/_ (6EXR_Z#'_DK#_\11_PM+QE_P!!C_R5A_\ B*7L&.]CZ.50JA5
M  P .U+7SA_PM+QE_P!!C_R5A_\ B*Z3P%X]\3:UXUT_3]0U+SK6;S-\?D1K
MG$;,.0H/4"AT9)7$>UT45S?B;QSH?A9=E[<&6[(RMK!AI.W7LHYSR1GG&:S2
M;T0'245X+J_QC\07K%=.CM]-BW J542R8QR"S#:1GGA0>GOGE9O&/B6>5Y7U
M_4@SG)"73HOX $ ?A6JHRZ@?4E(0&4@@$'@@]Z^5QXI\0J<C7M4!]KR3_&KE
MEX\\5:?(SPZ[>,6&")W\X?@'R!1[!]P/HB\\/6-T"43R)#T:/@=/3I^6*YK4
M=%NM.R[ 20Y_UB]N>,CM_+GK5OX=:SKFO>'!J&L_9RKMLMWC3:T@4D,[8..O
M& !]T^HKKZ\^O@:<[]'Y'71QM6GN[H\T5F1@RL593D$'!!K;L/$MS;D)=#SX
M^F?XQ^/?\?SJWK'AU=C7%BA##EH1W_W?\/R]*YBO(DJV%G:]OR9Z\71Q4+VO
M^:/1+.]M[Z$202!ACE>Z_4=JL5YS:W4UG.)H)"CCCCN/0UVFDZO'J<.#A+A1
M\Z?U'M_*O4PN,C5]V6C/+Q6#E2]Z.L32HHHKM.$**** "BBB@ HHHH ^</BE
M_P E'U;_ +8_^B4KCZ[#XI?\E'U;_MC_ .B4KCZ[8?"@-W1?!NO^(;-[O2M/
M-Q DAB9_-1<, #C#,#T(J2\\">*;!U2;0KUB>GD1^</S3(%>K?!3_D3;S_L(
M/_Z+CKTBLI56I6 ^0**]3^-FE6MKJNFZC"FR>\21)L  -LVX;IUP^"?0#TKR
MRM8RYE<#Z!^%?BNX\1:'-:7\CRWM@54RMUDC;.TD]V&""?H3DDUXM_PB?B3_
M *%_5?\ P"D_PKL/@I_R.5Y_V#W_ /1D=>[UBY>SD[ ?+'_")^)/^A?U7_P"
MD_PK.N[.ZL+AK>\MIK:=<$QS1E&&>G!YKZXKYV^+'_)0KW_KG%_Z *N%1R=@
M.)JY8Z1J>J!SI^G7=V(\;S;P-)MSTS@''0U3KV3X&_\ 'MK?^_#_ ">KG+E5
MP/,_^$3\2?\ 0OZK_P" 4G^%=5\./#VMV/C[3+F[T?4+>!/-W2S6SHJYB<#)
M(P.2!7OM4-:U6'1-$O-3GQY=M$9-I;;O/9<^I. /<U@ZK:M8#C_B)\0D\,PG
M3=-=9-7D7). RVRG^(]BQ[+^)XP&\"FFDN)I)II'DED8N[NQ+,QY))/4FI]2
MU&ZU;4KB_O93+<3N7=B?T'H . .P %5:VA!10!71Z-X#\2:]&DUGID@MVVXF
MF(C0@_Q#=@L/]T&O0OAE\.[<6D'B#68DFDF7?:6SKE44]'8'J2.0.@'/7&WU
MJHG5L[(#PC_A2GB3_G]TK_O[)_\ &ZK6WPD\1#7K:TO8(Q8/*%ENX905"8R<
M#[P. 0,KC)%?0%%9^VD!%;6T-G:PVMN@C@A18XT'15 P!^0J6BBL@"N5\2Z7
MY;&_A ",<2J!T/\ >_'^?UKJJ;+&DT3Q2#*.I5AZ@UC7HJM!Q9MAZSHS4D>:
MU+;SR6MPD\1PZ'(I;RW:RO);=^3&V,^H['\14&:^<UC+S1])I./DST33[V/4
M+-+B,8SPRYSM/<59KBO#FH?9=1$+']W/A#[-_#_A^-=K7T&%K^VIW>_4^>Q5
M#V-2RVZ!11172<P4444 %%%% 'SA\4O^2CZM_P!L?_1*5Q]=A\4O^2CZM_VQ
M_P#1*5Q]=L/A0'LGPE\1:-I'A6ZM]1U.VM9FO7<)+(%)78@S^8/Y5V=W\1/"
M5F 9-;@?/00AI/\ T$''XU\T45#I)NX'4^.O&,OC#6%F6-H;&W!2VB;[V#U9
MO]HX'3@8 YZGEJ*[3PE\-M8\23137$4ECIK#<;B5<%Q@$;%/)R",-]WKR2,&
M](H#J/@CH[FXU+6W#!%46D?(PQ)#OD=<C">WS'\/8ZJ:9IMKH^F6^GV48CMX
M$"(H_4GU).23W)-6ZY)RYG< KYV^+'_)0KW_ *YQ?^@"OHFOG;XL?\E"O?\
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MM&=\N2,Y*+D@8YR0 !R36C0 4444 <YXT.-'A_Z^%_\ 06KA-U=AXZG98+*
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M';)&(),?F9'HQ+#^=>76%J^H:A;VD>=TKA<A<[1W./89/X5[*JJB*B*%51@
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MICP,Y.[.,#!S]*\6\):IIUM\(O$-E/?VL5W+),8X))E5WS&@&%)R>0?RKIM
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M?Q1_:$UU']EO#L^SNJYW/)G.5/\ =%>K6OA>QM/%MYXDCEN#>7<(AD1F7RP
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ptct-20211028.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/28/2021 7:58:55 PM-->
<!--Modified on: 10/28/2021 7:58:55 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20211028" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20211028">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptct-20211028_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptct-20211028_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ptct-20211028_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/28/2021 7:58:55 PM-->
<!--Modified on: 10/28/2021 7:58:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ptct-20211028_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/28/2021 7:58:55 PM-->
<!--Modified on: 10/28/2021 7:58:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ptct-20211028.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637710479352369246" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637710479352369246" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637710479352369246" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637710479352369246" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637710479352369246" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637710479352369246" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637710479352369246" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637710479352369246" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637710479352369246" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637710479352369246" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637710479352369246" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637710479352369246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637710479352369246" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_637710479352379253" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_637710479352379253" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637710479352379253" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637710479352379253" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637710479352379253" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637710479352379253" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637710479352379253" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637710479352379253" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637710479352379253" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637710479352379253" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637710479352379253" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>ptct-20211028x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20211028.xsd" xlink:type="simple"/>
    <context id="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_6y7UpqkCF02x21GcGBJ10Q_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_Ph0ZH-iQeEyaqrHLrH7Ysw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_YixKN8_uF0i4OMbtNOLWCw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_xvqAwwFfK02qYi2AblWT_A">2021-10-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_9YavHJbpAE-vWnZRlvVJfQ">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_sDsBr8UoCUypzz9KU4XC5Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_ViXkFhHkHEunBN_Qp04wmQ_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_Uab-wYMSOUGZ1x1hZXh4Qw_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_2I3YOsu_Fk292F4WpZ3Sag_1_0">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_QhW0NBy5LkOREe7mNJmKaw">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_Uvxj20NVkkqDwVH6ZmSukw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_Lllr8RaK4EWjjyVMVjd8RA_2_2">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_7s08p0K1skq0Hk5cN7wE7A">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_A49I7Nx8l0KS4MLO9WSldw">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_GelM5wQuWE-329eThAhShg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_dtJCVijhoUCtw9gg4xBQ-w">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_7ojsDC7dC0uj-weYswNtmg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_8XjRNoRkFkq8eJYTcM_zAg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_5By9SucPgEW7yX0bJIe4TQ_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_D6CoK4y21EWB5_657CVgQg_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Tc_7FHcYnJmvUeWTqztBVxvUw_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw"
      id="Narr_DaVNRNafS0GYNVzNiyyNOw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139924344475768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 28,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !<@%Q3EXJ[',     3 @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " !<@%Q3!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %R 7%.Z1"95[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( %R 7%.97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 7(!<4Y:X=Q@_!   ;A   !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( %R 7%.?H!OPL0(  .(,   -              "  8(,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ 7(!<4Y>*NQS     $P(   L
M     ( !7@\  %]R96QS+RYR96QS4$L! A0#%     @ 7(!<4QPX9>H_ 0
M/ (   \              ( !1Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( %R 7%,D'INBK0   /@!   :              "  ;,1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %R 7%-ED'F2&0$  ,\#
M   3              "  9@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(  .(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ptct-20211028x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ptct-20211028x8k.htm">ptct-20211028x8k.htm</File>
    <File>ptct-20211028.xsd</File>
    <File>ptct-20211028_lab.xml</File>
    <File>ptct-20211028_pre.xml</File>
    <File>ptct-20211028ex9914df365.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ptct-20211028x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ptct-20211028x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20211028_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20211028_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20211028.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20211028",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20211028x8k.htm",
      "contextRef": "Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ptct-20211028x8k.htm",
      "contextRef": "Duration_10_28_2021_To_10_28_2021__ypvmuVEOUW2RETeNs5Tgw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001070081-21-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-21-000035-xbrl.zip
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MX?)ZU+;D<C^)==Z:0P\_3KGXU4@CG.HPOX,"Y+;D+75MH$!AJ:R$46VY;,!
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M1'!5XL!9>S.4OTU9*5Y56C_:Q:]KY,=8]D$;?/A$Y>.?4$L#!!0    ( %R
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MGED^#-NG0>WI'GFHM^_&K!8-J<TN_> )M!QGIK;5;,_5;<_A6V$"WB8V@ R
M,(,DLA,T!LX(-$$P[(_(.5B"BX(IZ(4P+[/]4P;PI\TR2#_B?(4X;!#X0I^
MD@&5G>O!L0;!3N##^7I0S=C*&Q&?Q>#W!TX"[DL&:S.W8#RV)_!S?]3U>A:2
M0-VW:(2Z.L:JTWF"@[)EHWX@MKP!K>S"_($Q=\*2P1Z8<0;<G-,8K$S(_(MQ
M.$,X*KC83@A^@8_&ML>"'@RK[]H%R(3JR =V30$1<7%"+C@1W&"I<OW+MOZW
M@ZY'_Z85@O,S4R#G#N.3 ' 3+V/:8>C"JD,GR+Y%+@7'"</HR+P#ZOHQ_ ^J
ML@_\A(IRZ+E".9:#>Z51G<O'C^$H<MQ4B9V'+OP"\QM<Y+:/AQ2C?O"4V<">
M%W3 _B5#=)L%/.BZ(08:Q\8QHAX/NT\VCU;NGQ3+,@+;3L)0H(/KI(=A2K1T
M2HJDT0[#)Q1LI):;R!Q< /^->,$'#^I^"^P^1S6(M3AB^-$T&D7#BH.):AV*
M:*> 4! G KCP>^K,,#%[E!EQ#$/!U !Y=@(!.0 _Q4\,! -Z5-+^,VAS]^F:
MO$/T5B;%+5E_'NM/!S'/'P./ F,$881&'!6@B'F.0;( LJ#6R'M&/6"U;^/X
MZ'6/^?9((=>?__/A[IJ<7_=^_L$PZU<8(2*?J<U+@<#7)/]Q>ZX'GQF6^.R.
M L+%WQM7,(4+!6.@<2Y4,8)6P>W@1?+)HH#9_9$7#%P;))(-H)%HY#L@#8R<
MO[NYNQB#;LF!)>; ZN4$YC@1KA\ 5N$BTP?.C1+;9E'433R>@+69B_)32(K8
M'HVBW+45.OSFT^U;P&]ATB.?:/@ $"H5+'SCID\Q:EIDZB7M@>[N<:^%IQG\
MX)%7)XW%"&6+<HB&90(($BF/T6+$CMHHYB#=W#@)!P<T>>CP9(1-0Z'GTP@3
MRF.6X8&A\<Q:&K&"%GTJBO_(@$\HFA+$?<64Y@13>,'=#B-(1;D^;$1IMU&T
M^9%63=LLMCHOI\,[N'0!#[KVNN0IEJ?UP\5CU/B?JT+]X.0'*6F,*5)I4PK:
MG-'0HK!SHH!P\EE>S#FD/="](#@/-=H%5K^DWA,=16G%7=-2Z\V?KL!9<EB8
MZMKI0L-]E9UN6(]Y6D'.R0#G39;UGXEJQI@:(6)]?CG3SHC-/"\E=_X[FL#L
M]XP7Q8IR5W@8L<OLAZN]J+ YGD3F./ )U, /")+XLNM^9TZQGE@,,ZOQC4/X
MW\FF4+#\6!$:.\4/-_(CIFTLKC@:VCD.1*'3E,KIX'*_8G(<DR_M-MLL-)./
M<4MO@H?21\M8F9<@BS!L7@TR/Q,S62."=C(M$N$F<VZ5"+H.'<14:;HG*^//
M,JOL^U"TG7KB#.RP"(\:8\N*='R%*_Z*L\AILOH<Y2*Y?__<G]%:E)Q.!$<&
M](&A0]G#C*J(Y(<,7$682.H#!GXO0#=QOKCD!5I1G#@NJ&KRLCAZ(_;E0>@5
M[+LL?KP+U@VJPK0%E?WIPWWM-M7,QBN3("[Z*P'PYK."GAZX<6#W ]_A3P!N
M\PI9 %B!+91RQ-R_$^#S2>U,01IL=\C?6)+),E3)V9*S=\[97_YS6WMWG7L=
M\SG['=#-"9EK]PF-Z7=P/)9Q,#"K^<+\"LFK>^;56S^$Y>:AW%1'OOMP?ZNW
M"TJ9#1X#)W"BF,8IZV)9=58DRQGVYLM_/KRMP;?<@E,L:KIXSHVE3C+6T'(O
M>:J"0/*R=(AWK8$% ^NDSY,B(_(8>(D?,Q9RCW:4[A)HZ"VNB=\GZ#OW /_E
M=3:9HS%@,1>,H/,G,+;[R**%[@0\B#B3BPQD*D-IAS-2LZ3/63D:0] 9L*E+
MHR %:7^"=!,,P ,'R>&"\HDYF%T *_!5Y**C5'Z <.1W8-WSF_>?OEZ08 @<
MB_LNA*B J-6NK]_>\"W2^ 2(-1(UKZ'80$T^UF"N?D" %QWB,)N&G>#[R$-Q
M.,>O7L##+O2-&<T) 4FEL0NF':1JNDY-RH:4C;W(QKNT@/)7-_""'F[S_>C:
MS =VO1X.O2SU=_[KQ^L+SNB<_<<L+.KP!1.+<I:D W(FFOQXG7,U3[A/0]:5
M:=^-N6]75'E-B4\',)S__]Y[:&J:U6@VZLAC],UB29Q_2$?&G4MRD]/<J8@G
M.-6964YGG_AI'&D*1*^G.1#M #NJ)N6Z,2G7C><F+S<AR6RB:#E)]I06FMKD
M_A[>]/#M4\D/(2FELCZN(\-WX:?EI.!_LY#A]ON6VLR+\N;ODTO="(4#61H*
M?SR>;(UOY==;:GVMMC3IDD@N/P"79QN:H[G;/Z@=!E&4[GP;[Q\)PK@;  NG
M/-U0K9RGL<HH#$: ID?\Y\GRT^*Q%H:IZMN(U9QQ"N%J&04Y76L<XGMF8TWY
MEC(I97)?,IEORIG/W\(464W5V$9D?JR;:YL=C$GQ<TU$=B%D70^P!\C0^-@9
M !W%0?(B=7S(OKL1+X!/"P>Q'/@)V![_'>]'F[>+2 J6%*P]I2[$;J=E4E5O
M;F>(?@3'L/$\J2IN2<)=[=F)@9$RO1=);$'O,A@RQG]3<>+6+)+2(Z5G/](C
M=@B%_- Y8/ITLY& XCQ-!V+ #Q41-@ W'.&^D^_N !YZ(W+S_ATQV[EW.+5)
M"EL 0M9X"YFS5G0135,U<P$3^Z14\C8)\?M+A'0<$5N\KVN\H2L.W5Z/A?RP
ME TW;2D$6, 6.PYS(G%C-\?9E%(JI70_4OJ[>J>2WZZOOY)S<;8L;F"AMHVG
M]CCX0R!RB+CGP[?=(? U;IJ-0/RPIL3'1,HC\X(AY_+S;S_3P?#J[04/._M1
M(1"BJ:VM#&7;5+4-#.78TTSM9%2L2'3]1Y#+K!@AGP:O8J0#L:>W<#A+=J;7
MS%ER4AZE/.Y''C\'?HV+8RI),X*D-]<7)/8=XS,HO2" !3%"$ ;]V#3JP]P#
M^R'=)HR"!YT)TY-V/"6.+7/-[K6)[ML%\+E)[U+0I*#M1]"XD$7 (C!&)3U7
MW4L-P #4O2A8?V3D_.XW+HK7,T;-:A=<S$UL6F-=&5YHT_  KW%8I&#6>)IW
MB.YDT8&E6%8$1I!E!W:B4/(("O])M#8;HUTB?7+CWN$W[DF-)S7>+ER+3*%-
MZ[.&M6:D=\JU, K:[!FN14-;4YU.NA;-0@9)NA92T(XO:#=]ZO=87E]%W3 ]
MBA/8UV%=QH\ $HE%CJWY+4Z!'[D.2\,^XJ"\;2'S^G4"XI33?+C;#)4?/>O1
MM(YX8L+B!6AI&,1XL!ON24GB)&1338CZXR$>-0L_XO&">#3%7XD;CTAZ0"FV
M<MUS/>CM5S>(YYQE+#[EQV5 ZSX64B,AL0RZ>+8AM:%=85O';6:Q.-L+HJG3
MF?26U!-23^S)(+.8>%@C(<3=- N6;,.B!MX,AKT!D\B"!,G7Q[5_X'X!BZ(3
MAEH<3(&X[8 ?F(C9?<Y>$;.34&!2SO\MJZFVQS4X\9R3XZ?LG*[JI#-^_RVS
MT]=U17*XY/ ]<OA=G^)N<#>*DM0_@F7@QV:YXC8/T+&S["M@5E-3+*NA:/HR
M_MRZ7GTO9VDM6H4=G:]>B8)RW$N1'BI$WB6>1_Z+.6R^K+]E]S?!PK\+^#%I
MLJY<JIK=J!KD.YA98:O^W'+;\2TLDS>#Y(>P(\N.<I85D"L[T15O#.-:#&\-
M&WN/6+(PA/;=((G&EY3QXHIF^K[9SM^7UE:*P.%$8")'BJPX'=1<D_-;>D-P
M<LMLK,/Y+2-[O]&0G"\Y__"</U,A\ SN;V;<WQQS?S&XSJ*8E^,Y>5A=61E7
M%QL[-&W<WA)Q:F;BU%Q+G.0VSA>VC3-G]O'FS4^,1G@6U]C%/OS\ME[RLS<?
M?'&(![^(#$/GF-C/ZDZG;]:;O&^O*#FH&?!DYO1$9QZTQFJ]4+S!X]Z<<-A$
M$J$PVZ!&:9HAXQ^-6QZD-%7)!SQ#!-4M7C,DAK7D_515L W40U;.OJS5B8GA
M@?3I(3]9A<.<K^0EM#!!WFR'V33!PU6H3WOBFPFF.N.5O3_U0372"%[F9$,"
MIA?3C'BQQ##-6\!WXI#YCJ#:N)^??S#;5U%V/H6R1H\X7Q@<Z&IQ?C=6<P2A
M6'Z>[,!/11*$YS)X^^-V\."D]#*YSB@E'(XT.^4[Q@U"&#;CYUKX:9H&F! Z
MX66-V ]\[4]QVD4Z0:SY'%_VE/-<>N/##0;B_%$V%I'6 1_!"X('=6RC%DS6
M#_BN(.JE1X8_"H,UYVT0$Q'P6\#?_!(J6)M8M!(R.X 6/%?L;L@*.)<17Y##
M#5'HAN+\'9$(BN)"^)(LFTZZ#W)\"B!:*SS9U0N>=G,;(]X6OEN5OLS*K=)R
M=ZP7,/+[AT6'I)?58BT]H?J9>GW=-3KV!8JEN(A7SJOR\S+7NW>\SN_F*)S:
M<B<R\WIZ8LN2^2X"JV6Y@N&@BRCK+<MR4<*F5FAFQ9>9I5E!:I@I?UE:*DKS
M;U<^U/VU4R-4Z]D86\4Q+D" Z]%N$@+>@!\7>*[#PQ!W8U<77+LOF2L>K<""
M&R+Q#59(S-]06].KM-B76$F$LS?G'"4&"8S1B7A AD';43^[BV>(ATSRWX L
M]**H* KL/B$WFFKR@1$^C5_.\&%>4[Q6U%'0!Z_524F#,H1U84"121G5QN&W
M5$!G0HDTB8,\DEA7F_6?1 0Q&TK:15O54G+&_!P.@#$P=BN/D\ZY]"E5,[ D
MYD]%]VXJU/=LX6Y.,4I3Q2<%3N$S+XIRG4]F<9QD^@0K/$[_$WS0C\BMC_!B
M(J6<L_Q42',A232UW<H5;ZKG=15'P^6+9"9BCS2;8TA7HP[^36M]>[\N/:#O
MYEXYI%2S-52C\9)6/U<6]=7*PC"X CJXLICR(/'_FJZV5^F&8MYC&+):>F$?
M^8QWL:VK,'A<?4;?+G*K)RBJFV=3)B:CTY*6^>*?K<6J]9:JM4HJF<U]Z*'V
M.H*9OL'+,JHBMWN@5EMMK*7'CD>NUA2U6NHX$ 9C*;@ !$O\5WL"F+G;V-H;
MJKE?E58JK@ %7G*N*!6Y6M!WN<FU@1 UU=9<T#DC1-K>7&;)5F7WJ/>B<];S
MJ"5SI(:[57)9VDCGM-?3.9L;;M Y^HL2HF:YN:)4Y&JKEE5N<FWF_=:W,=P+
M &8=?, R8<QE146&JD]2@G?Z+:WEOMP:/U9*/MI[1H<OG1@EAH![F6U3+OU<
M@/?2B3&!XEXZ,4J,T?:B% RI%.8BL)=.C!+#K/W(05,N_3P0==+$6("43)Y]
MK 10TE2KN/]"M]*A?Y[= KLY:-KCI-JKYU17LYG5M RZ_K@%VCGT+!:6N"R>
MEJXW%$MK2/2R KT<<2FGZ]KX6AH\S%FH6-J,/P4*J0!_3JSS@O**EJ$TM181
M?[:'(4=C:!%Q JE:L94M)^Q$K:\FD<@ND,AQ+4YF18VTZF!3:]/:+__N2II-
MK:VTVZTJP8'2":< #&6S1T"G9Y@CX?=7@($-PU+TNKE&QL.HBA^O%U=N[,;?
MS+OMIE2.?*F,2'4<?DW1=+U*_OZ:SN%<+9QO>MB_5MXS2C@!&E4&=)@-1=.T
M2D&(*JS_D6%%)6BT=S!R C2J$-P!6ULMM%.%]=\[ CH!&E4&4:&MM58#*K/D
M@(JCJ *DFIL:^39Y&^H^]B*]++QU5'KL#)&9BFXT)2([TL8C2<6UR]6J+6=6
MVSJM7?F58" )^D[@!(!*4''=;4P54%6FJ9AU"1R/M:5)4G'M(KV2R)F 7\]U
M"A9CSW)O7]**X'/^!J;[(.:G%XMM3/(4C*,#T^.1:W>XM:4TB[EP"5SEB1E5
M(7+YS]G8785O2ZEK]1=QNL9S"TPE5"X[C:I^M$<EB%S^ T%V!K2;@+2MC96C
M1-H[0MI23$_ZR)&=E=U:NM+6C'7*;LN-U/752/U+?LE+>B^//'1$'CHB#QV1
MAX[(0T?DH2.GACD/KA3DH2/RT)$2@KK#RX$\=$0>.I*CIE:I0=/L=MP<,IFJ
M-12[%:,8[QW*#AZ)J+=-EO,D5OF4=BM:2L-L5PGE5")P)#<KGM!FQ;IB69M5
MC\N]BJ7'196@D=RK>$)[%0U3T;3-S@60B3"Y5_%%[574ZXK66%TOFM^L7'X\
MI:MFNXBGZMFMGM># $;\MSC]!8 5M?]*W) YQ/5CZO=<O)N41A&+)<BJ/,@"
MMC9;LHY3HBR)LA;2K*U8ICP11J(LB;+*2*/*H"RSI=0W/'U-HBR)LEX4RC(L
MQ=3::Z"LDM?Z39ZQ.7$@3 ZSOK&(T=#N$^H[Q&&/S N& P8L<ZY?2&15?61E
M:DJK7JG3]2NARR2T.B5H96QS)KC$5A);26PEL54!6[71V&X<I)'@2H*KEP.N
MS,94)/.4T=4=\^ [/87TF,]"ZG&419V!Z[M1C)NL'ADY-R30JC[0LMJ*T3 D
MSI(X2^*L131K-+=QCR3.DCA+XBR)LPI!S3886V.SH*;$61)GO2B<I8-'VM1:
MJW"689:[5A#D-N<0@\^-6.,+XW23WT(+7=_TJ=]CQ/5)W&>D2]V0/%(O85@Z
MZ+ N"[%T$-&7#7W!B#'%!3]&KL/$#7,2@U4>@ZUS5:^XHU?7E!;>K[6-CCP*
M:*OVN7)'0G'5)EIE8!V>[E@)5%=M?C@2S*LVT8Z$^ZI-M.H 05VQ-E<]Q\"!
MU6:((P'#:A.M0DA1:;=6)^0,M55JI#AYM*&FMHH9N>R8CCL6QQ[C!8Z+@:&\
M%D]>BP<CJ54!&%9*)<H;\>2->,\0,7D?7H5Q9*5H)._#D_?A/4]1R63C6IA2
MBM@N0.9)B)BN*9:^UCWLY8:A:]^%%\R<LR]OQ3LZ+CV!JRI,76GI\LQ*>2M>
M!8G\@F[%:YI*P]RXB*WDUV*=  M*?"POP2L%D5_.)7B692I:<^,SA"7&WA'&
MEF(J+\%;@^B-=E,QUKBNOIZO4DDA>H''Y@/TCT$4D6X8##*0'OC;@_/2B=4Q
MH7>%V?^\C5;*VFRWKD365;\IKQ(D//;]>CN3L49#T<T-CQXK]WUZE> ?"7JK
M?G=?)4AX[!O_=J:FC%9;:>KFQGI*0M9-(*L4LBI>)[@S(3/-AF*VZQ=KY(2;
M5<&;Z7RG\.8'/V8AB^(L$ZP07UYL<0([4L\-76EI&Q[P=/1KTLNNX(Y\*%#Y
M"52NK:.Z6F\LD0_-;&\#]^3REQ7,E9] 1SX-J/P$*M<.T&4*Q#*5AJ%5"H>5
M?_F/?!!0^0E4F;V=YZ:A:):V#H32RYVSF]C=.3X!J "BOL1]%I+S%$)=$->W
M@\&V4*K$A>E' 5LG46)^KK>49JL:<*S:F]]+N].SVF0]H:V?!HBB96V?YY-,
M57&X6&VBE7:':+7)>D);1L\-2ZFW-X]MR>.)3F8K:;7)>D)[2T$4C;JQ$@2?
M2.%JAW6#D*7XE\3T>Y96E"6L+[V$53=-Q;(VC)?*&E99PWIH<%ME(:LWE;I6
MES6L+P/'5HI&LH95UK#FJ:%F6VF:&T;#90VKK&$]-/:LM)#5=<70C;42L*6&
MGJ((8U49:XXX.\QG73<>IV-E"E:F8&$DYF8I'PD]*YQKK1053RBU>FX8BM%J
M/0. 2BZ2&/3EI4XK1<53RI2VMXB6211:U:QHI:AX0DE0= L:ZVRG;*A&J:'H
MRBSH9Q83#S.A-(Y#MY/$M.,!+ T(P--!X,.( ONA'WBPIB=VYNY<7EG-&C_*
MLW27Y$N-#:V3!*VG<)KN*AZR&6[:WKEPO9P3<,^MMF*U-\\_E/Q0S!,03HEB
M3^$(W /Y B_ED-ISLZ4IEKGA^7\2J9[",;5'\@5>SM&RYZ9E*BW-6@E.C4;)
M-JHN%S^MB$Z7I@UU36VL+UI[/J1H%E+_P=]B3HT"L6F/D:A/0^@L2.(HICZG
MJ2POKFAY<:F(<?3CCPX\VS+7#1^8&,>N "X5,<I=$7Q@8AS]2*,#*X4R5^D>
MW#@>M]ZV5,0X^M%%AY:#$A?2'EP.CEL2>SAB+$A+6FJI@-\R #5U/I&5GD_[
M*XU<FP!:(H[K)8"FR+GKITAJ,JQD!UXTI/XO9\;9:MNHJ_52YJAS8O#CVPR.
M]1<!X:>^&[,:S-EFE\.0U9Y".H1W"/YI:DJCU5#:9FN>W.2D,M<@E:D:1S@9
M<U>$P#]64['JNJ(W]6<[E64L"I%^Y:'\RC*M_N*3'U&/UIIJ>XG$S U>O[BZ
MNUWH&%"T9KNIM.J6]$TK7UYW3/?TQ.3":BB:U5*,UJS-77B22+FR%-/.*LAJ
MH8;.$$YJKF2GR^B&+!1>*O*';EQUYOJQ3N!Y-"R\O9<]7^7-=>TM"?ARJNW4
MUH;G9<E2.UEJ)TOMUI$LS;P@LM*N;+(I*^UDI9VLM)NY!%2M;WX%J"RSDV5V
MLLQNI60UVBMK[,RRH=?ELJ>O7V-GKB]5!Z^P>]V9Z/%)?*D3> YWX"[(-Q8Q
M&MI] ;S9(_."X0 D@H3,#GP;IL0OJG_]JK.I#R*+;F0E7OG ]<%G*ROQ9"6>
MK,0K-V(]?)9'*@59B5<^Q'EX.9"5>+(2+]V#957G@)"FJK5GL=9OU]=? 3;-
MQU.ENG=](^2?3E97K0DTO$V^L2Q3PM'PO+TYF;?734UIU1M5P#.;3NV(Q4U[
MOUE]LPA?RL_&=/G7-FF^LC-TVU#:[5:%+D(O(?L>%YN4D"![O^A\6>9KRO0:
M:FLK:U2FF\@7+;'91FND20!QO"O%M[(L6G&?QI9YH]+S9J.M6*:VAE-OE2KI
ML]RKGWOY&8NB2U%Z6.O0B.'>D &>/L_S(L^^!$T6^5;N(/K%Z$'1ZILY6Q(\
M[*K.\*4(2]5.E%^(3!3#V-BU.?8>F5)QP@O.F<C5+^V.L4WU0%U3#'VSZUM>
M(L:1C%_V+6&;,K[14-J6OA)  ;-7!3]9H*(WK$#['/BU%6F39]2=5;_J,B7I
M+G(O)T.3A?!+;RK-=E/B+[G/:Y%*VBY:?&([NA8Q6<M4FLUM<D5EIDRI7!>)
MV,K%''O7'">VNVIQ,D##^TPDB'LQNZ0RZ=A!IJO*1%E/.O"V'ZN]"NDUN)-?
M'J2WH?@<; /4BFU;:^_:,HY[,CKHOV9QWY8UQGAK;=TR+L@=\Z#%GD)ZS&<A
M]3AVIL[ ]=TH#FGL/C*YB^O4=W%5"DK*G5_'9I<R9"U?.C'DSB^)B>72RYU?
M$@_+I9<[O^)+PU1;E2D2K4^<]3FQ]2M:C<>JNPML$9XXQ6U@5ELQ&D85L$VE
MT-^1=X'M@9VKL0FLT=QF&\DQPHL58N<CX98*4>@XV\3V;;^JL'%,;V-U]6;;
MF(^$/ZK%S\?=;+87?J["9C,='+*FUEJ)(_2J@ BYTZP$*9P*UP[KAM(RS"H
ME#*K\W)O+"LAR4YE[UE3:33:VZ=L)+.4&""5ER!EW\%60I*=RB8WLZEHQ;T^
MY<5CY>6%LN^#*R')JK]5;GS(O&$H[?I*"*A;>#Y]-4"@!1[Y+ A<;[O<6JFF
M4]LY-Y^:B[?.<?+*K7/K9 @LI6YLYA%+/'D:&^46EOCO,D-69:JL)T":N,?S
MY>R=*Z$$2L1Y4COP9@DJ-^$M39(8BFY5:1->.27FI/;I[3)+6&6JK TS];JE
M-*WI<RU?Q;3C,?C7<1\7C?8&>NJ$+HSN/?,>&5(21TK]J+:.6!BM97?2(9)I
M</5'6DOD9&W*;2U'G #B[WX.OCO4?NB%0>([-3OP@O R6W';8S0$\!KWKR8_
MR#*V4V3(>"1C,E,;RSR_T5#7U6:>L$Z'/_D,F<\4+-9CM4[(Z$.-=H&8E]1[
MHJ,H9>FFI=;'DIYJ0Z0I3"V;UH!^3S_1->VGC&<G!I(]FQC),(A<S-A>ALSC
M4'RJW0)5IKN8]\W=X.:9:,+Z2J2&(M(P4UFQ-%6(RM?[&W+?9R$=L@2X/5+(
M!]]6EVR7W$A"9K'^<@GA8+]A\@V@K>(PIP(JF]%O,OQREPR@OQ&Y"7RNV2A>
M4O\K]:AO,W+79RR.\JC+?!)<AR[UMB7 \FLK4Q71GEZF9VB)LS?GKD_B?I#
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M)P2>]Q72\X(.*#&0OF&?A@-J\[G"DU0,@-E!/XZE _5E )AFI!"'/3(O& [
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M)!Z86Y@+>BRXT@<)BYZ\ [VOK$V6X0#[.,XU@\"QD+M<Z-J WJ%V'[DX<_^
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M: +MWJ,H#1REPKEXO/ ]$&H/?87)B 6V4S"4/">BC!,BJ(RB9#!,S606?\M
MZ9]"$4:<K822L=W03@9X!PEJ_,"VDY!;#%'VO8("[+O-8/DH/ODK<4/A:8&]
M5E]W<&^88*:99=WX;--#I12>GS]X#%QG5?K@52=P1O!//QYX;_X74$L#!!0
M   ( %R 7%/RN!,4R!8  )ZR   4    <'1C="TR,#(Q,3 R.'@X:RYH=&WM
M/>E3XLZVWV_5^Q_Z>=_]C5892$* !!UO(>(N**".\R7521J(A"1F$?"O?Z<[
M"89%1]P=F:J1+)WNTV?OTZ>[-_\[[%OHEGB^Z=@_?P@9_@<BMNX8IMWY^>.\
MM<O)/_Z[]2\$_]@?A#;_E^.0^6N[<8P,1P_[Q Z0[A$<$ ,-S*!;0BW'=;&-
M3HCGF9:%MCW3Z)#X$R53R!057LZ(.4%1$,=MI:O=QC[4XMBEN+20$::+5.*F
M:"&!SXIR5N1% 15+>;F4%]'IR?0'44W'IN9A;Y3T%+[-\ D@(E^<_U&3>+>F
M3M"AHZ&#'?C&X 51+.2YHH:+G%0H&IPBPZV<SPM2.\_G9:60J@E^-KL!H!=0
M;/LE@Y@_5[I!X):RV:'F61F?Z)F.<YN%%[03/,<+7$Y8B8J/BPX&@\P@EW&\
M3A8PIF2'M,JX4,DR[=Y$258Q+2OR?"Y+7VN TZ3X<*;\1,WT[;@H5&0$DP#'
M]>:ST<MQT;G 0D$A^^ODN*EW21]SINT'V-;'H)C#@ ,$3'R9(,2T 1)"29 -
M/&S[;<?KXP#(!I4*>8Z7[]%4<@,]F*@$'FBFD]&=/N,,@1?E5)OSD?6G!D5.
M+-Q7\A#"A5RJHJ2X1]H/$JB0A;=IA)N/T'*,P*W-+L'&UF:?!!C1XARY"<W;
MGRNZ8P<@C5PP<@'-\=W/E8 ,@VS$--FMS< ,++*UF4U^H[HTQQAM;1KF+?*#
MD45^KO2QUS%M+G#<4HYW@PUH-0NO)\H8IN]:>%2R'9O0 N:P1&LC7G1I&@:Q
MV244J(&B\$P]@FH8-"A6=D*/(5D5>%6454HMM>6D[]21>]L/+ZKU\TNQ46V1
MFI]O=08KR,9]VCXQ2U4;.C*J0$<];!W8!AD>D=$*,HV?*RU=+8R*Y^Y-K[++
MBT-1V-/WM@\%_DP556%EBP?^Y(L\+PN;V0D8WQKD,JA,@ZK-70MWQJ">=OG?
M^YQY1JHC?./M'WO[Q2M_H.8HJ&UL^60&RNPDDH&5B >JF_A;FU202SX3/  ;
M,<$N=1DK4GGA$L'(#'UC)7Y-N>;GBF_V78OR6':RCJBY=!OLUG="C]TQ[BW%
MJ&)]>C:JDLH((VUR9QKTOFT2#S&@R%S-43DXFJ3L],=;R:/)VEU J6,D=R!H
M7K #9F:+PLD)/"?*R7?W[\9@&@\43=XD]TDCV0ED)9@=HS*;DJ,9F>OC(3<P
M#3"S L__9\/%!K74G$7: 3S)Y/+WSSRST[U_Z/@FI08T9 %9;IG INK5+8*]
MDN8$W8WI)N9]Z2;?M:$37!OW36M4^M$R^\1'-3) #:>/[1_KT1/X]:'K[1\;
MK+1OWA&H&I1* BDT&SC]DI!Z1!4/O:<8XK!E=NR2#B0CWH;F>(":\3<9J CY
MCF4:Z-\\^Y>48+IKSNM(M95BK>935R7=&0:>""_9W8 P+&J.9<0?CENF96Y-
MW]1,"S@I%D6H\I]_RR*?V]C,TJJ!A.YKH6L6%T_I2AY>/A]RS&19%711DP60
M6?C#JY(AZJK65K":TXR"B,4"*1AMJC3P>_55F^VH4)Q'M)6M\]I!J[J#FJUR
MJ]K<S&H?3Q+E123Y= AN5BOGC8/60;6)RK4=5/U5V2_7]JJH4C\Y.6@V#^JU
M)=:CYA=#^B26+\O-_8/:7JM>6T<[F4H&B7Q>4I:8C?GR):C=K3=._OFW4. W
M&#K?UOW;B0?-+>:E4^U:PYZG7IG#HYJLAKN\*=5/M*!6/[ZL#/X N,P=10PP
M[1I^<X9XKH(3YBLX4&^-:JV%&M73>J.U%+G7Q_!IZ/DAM@,4.*A)="ICD4 *
M.>1X2,BO&FO1 Z>-@BZAA4(/_%( N#K4N]CN$%36 P2O!24G+6GT8L@'73,@
M'+S72<GU"#?PL M?T!$-Q7*#N(X7H-7D'H8/%E C0.261@0]]IH8:R6$DEZ]
MA5Z-(C4_5\QA4#( E#[4VC7P: 3P$'N>WCUEH[!J-#9+*>#A[4UY,-AM'_'B
MS94IEC7KLJ66Y[.Q,I^+ZWK@:#! %>5U1*%>ZN9G&NOWB!DU2,?T:;0OJ,&;
M%",H5_AV_U!SRU7N]M+^W;!N+P[;9W^PQ*>M"FKM5QOET^IYZZ#27$<'M4IF
MR0#/\H-7JT,,NIS2A:J6BM.'YD<(^ZCI$IW&<0QDVJC2Q:!BO+4OCM%XB)W/
M2U*1:(8J8SVG2G);5!51D%0LRGQ.D^FK7#S$QDG0T#+/FE?UD73*<^?G%S>M
M.UG9V>VHHLI/EY3N#AJ7US?'3D]L'H:GS9.3;OGW $J*TR7M&S6_K[?=0[YY
MIQQ?5U1R>KQ?AI+2=$F_=K9GNS?]G=XEYW=,K.9N[W;.U-QLZXJU?<SE3EL.
MC_>[5TZC1J[JE3*4G&D=<V>]YJ#IG/'-O;!V5<6D?'36@9))ZP'6+)*0(([T
MZ(YE8=<GI>0B3=8"4*(;R2J-;,5A\81>+'"&P\!)'D11,_9D(KB6CE=%91B_
M4&@X"X^<,/XH%3D#B ,O 34&08CX*#"2Y[?$"TP=6S'71?P3UY(3,L7\?](L
M&$- KU$._O/1_ZE@7JHM!^IO6\X@X<#DGIGSDN81W.,&@,4_!@ACQF9 )$6Q
MYCM6&)"I3K^.*#Y%\(2G2UD428W_!L9322"RZ.E\"BRQ_E98IXQ?6#+^DO&_
M&]:7C/^&),@&'K7(;V)]W\?]?.,1-$W(H!.< 7$]YY8.F":'T-' Z<#6'0]&
M]ZR])BU=<4([\$85QR#C^6Q_Q]_VY'.G<CYR[^Z4HW/I5R5_I@K,.7SZD'H'
M>', 0_D'1U*OJ-)>96@S0; H9#7[=U'(%U(+7Y<5ISEMU[0(M* 1;\Q6%^:O
MWFYWO[=?#>WMFGKF\M*@3]E*7(BM>)IJE5<*RI*OOB%?M?#P(,X(T5F54TQV
MCC5N<'72K)_O_1:&0O?WKZYT-@ FDQ9C,HG+24(A+Q<?Y[)/;9>>$JYA1H#&
MZ>M!EWCH,/1,WS!9%/_3R=*3/8V7!74^K1 ^A9X5I]\W?7])OJ])OH-&$U7[
MKN6,B/?W:!FGC28\S[4E;WX]WJ0>'8JL[9)^7Y!^DVX3JCF9M2D-DV4A\8^=
MCUD@2/#1TT:+S1'IO&'D14U7!1GG5<DP-%63!*SJ!:5(Y**$^7:2ACF>4=F6
M.4_IUG;J?+__VQC<&78U%Y3GS1&5+?L\[\IW.[V]SMFU7I?/SXZV._/F<_@[
M4G;4W.]\M=ZI]<[,FTYKOS](S>=\C5D:^34F:20YD\\M0W8?&ZM6'J3 $NMO
MA77*^.*2\3]%K'HA)?3W!'+*AN$1WX]_CDV;".,@CGB0NZK[H;K;$Q5Q5[IT
M?^>:N+-P !K8!E7B40>!J] +7B=F^+C*^KPQPX7$_J/=JQ=ZZ4LI7$ **W!9
M]UK.P$XETYUU+_G:]BA_W*LWJJ38KQWVC_!L6OMC$M@$KZV+3BULVFV36,9<
M\7MZ=>OH'9+\)Q##PJ-U[]1S;DVV GJ,G?/;X;7(URYZO9N=P<5^X7>_&?86
MPT[M\$NHH\\WMOZ$>NP=>?+4\0-L_3;=B4G;8\ORY 8^DJJ7U]>CBY.+:T-N
ME.,LP04F/HJ\S+_JG,?[:M:G!%EC/-+\U%,/Q-ITL86J0Z*'U#U%]7;;U(G_
MC"#74A _G+8@%HC*Q6>,;2T0-/IH,%>V[G/L*7A"<<-' ;&(VW5L@FP6!EY'
M(#Q62.F-, SX0.T9I#1>,_)TI;/Z#F:=NCAE /)>:3(S7O1YV>6/!+]WP^_W
M\GJM.*@6%ULZHO#R"_V:M??P:XX=$.)32K[TE#E#0EE2#HJUH6SQ1TWIY+BN
M7#8M8S%?1A1%KLCS#YN.C^;HS[ULXM$%*C4G0-AU+=#"H,.6Z^.>9@EV'0_8
M+UZ)XJ'X-K;]H+K:=!&*W2$&:E+7'AUC/XB7QGWU92FOAU_3IK-&I5QAVO.H
M=(G>8\LY@3,]Q_5,&F/1G"'2B.4,*'KI2XKU*%8A<T>H#:"#K3!],!P!@:H-
MNFC4-_NA%6";.*%OC9 /FLYOC]CG\0>.!OB+IJWB-:3>V#JA$.KQ$%UD%+]K
M.Q9 0+^CJ9 FS87PT>JF.8EE>ETRP9$V=>B.3^@F/5MHC]C$ V_PP(;:0Y8&
M@\H9,1/U:JWTW1GC'O('.6,"\&2?J6AS+4ZS'+TW\3W])G:?A4SA[<92TZFR
MFN-8&@9&"8!GTV;RTC,#X$V:1Q/:\62IG[*5>\0ZR0_.PLLJEQ,5TNJ6N\UN
M9QZ]$O0V2<<AZ/P -4=]T.C3<I9B1YL":4V8U_A1BEGH9!FCKE*4I'OJ3IO<
MZ/%C'E[<4T!PNJO(3:WG;H06B<17$O.QI$TMX:8KMU>%(JKL-I"8XS-0<.TS
M>;)+87E#86DZH#Z!#^S.":A_L %62E*,X+!R85YWG?-*,% Z'6FX?<8-OJ*D
MW'<3]>-^/B F@H0Y04Q)RL0.!V,YD?A,5'(I*M]%5$X]0FT*W8&/;2%#W1^O
MWFY/#,2*SK6_4RD:%3Z\!KZ^\@>UH/\EC0MTE]-3_7V:E1$D@Q-7M7B_D"=)
M4?3!4HZ^J1P=^'Y(O/G2)/^Z;M2<1F^W=R.3PZN6?J+>E;^3-.4()ZWJ"TA3
M_,%2FAZ8B'\T3)-RBJ/A*?%@@.L^N#W2O:*+!ZY CM)?$-V)$QZ+<ELADB*J
M2CXOJ)*AZZIFY$65*#DBZUB3=+$PG9QXO?N[J*F>JO&<\NNN(%SM\.W+)/%C
MHJ1W=N'7)/^B<U[A^F?R[=6N$9YVXL5D$R5SNM=R1WMJK5K/W^[*;N'8/;I,
M5@1]OH3'5]V$HIA1E&5VW3MFUZ4VWK(=MNU6,C?(RTM"O'>:HZ L^7_)_]^2
M$(G^EZ4EVC\LM3>VOU/;GKO#AW<U?XM4TI=,/;;H41/1'I%Z%^D6]OVQA_H:
M&N$AU+"C/%RZ#V3PUNAY.C(>3L-=""-IT_256</#+/,C&BJOTGRI)6.\G#%B
MG?V%&2/9^Y&I#)+$&AP; <GAR?W8>!(]+]*MT9D3[XBD!T;7Z= 95\R(,VST
MMCD^<0AB)(@:T]SC[-#\]DAIAOIIIWI9'/WBM<,#(K7.XI6$CT6>:*P-2-<,
M'+VWCOZ/S_"\@$#^T"VV0H)<>J9+EVWR\T!PZY7TP;=*JYPT#I^%M]^3D6/C
M$MF6,1?O%"K.D302A>KE=EXMY(N5B\Y9)\YQ?C1^VJJTEASZFJO;)ZS4]^'0
MZ6D*:MYF-UM+U' 2:+_?I1J8N+B[KU_9A_W;<W+9NKD+MB^&M^>#>)/>QYBX
MAGT#WZ ]R]&PA9K$(GJ 3K#7(\$?>?M;YD#/.'$'MD&G3 C21DAG"6SPN@=^
M"6&;'TTEEID^@AX00&6'^KD=SQD$73KSDNQH;9"V:4?[6:<29?@\FCWHX/Y\
M@QQ:I06+&RQ9)BD,;0&KN'1+;)JLF)K#$35.G%/AO),3QC73J9S[[U)U9[[X
MU,+[:M*5K>H#Q'^G8Q$>GPF-%@4E(.XQ"./]UE.3H#OXHM:HX7:3W[NJ7=S5
MS-&H5G])%LZ?YS._-XO-:IWV(WJ$KJ&8JY3,F437+J@<IO1!Y=@.FU ,?<)*
M 9[B=%HZ/&:!-A0=64C9B;5EC6CC])1?EBMK0U?@C4< +? =*#)LZS2O">LZ
MW1*4%J:'EAK8,_PHD=9X=#8SMXHG9S/3&BJ#%F"W60;[TL?PO=MYBY,A@WG'
M)Z;=M1><KOC1N'@8SE> ;.)DW,7 9"DT<1S]J7:&?Q$^4P'J__G71.0=ZSU0
M-*%MT*ELQRLE-$X=%AI#*C)6ZA N"NSC-HA%"5L#//)C9[^H9'*)KU\:LPD]
M6QA%1Y2BU#7MZM]]].D]6=GJ1DHO-(?&GT0DWA<,8.-D(DG,O"Y@LRS=9O\6
M%-(_Z-79B-V,W*:CG0L>Q:J(2E'("VI1P;(J*05#E7E>4C51(9JB\WP^I\5)
M*1_>[<<BO <!Z2.@KYA!#>*'5L#64M?!XXCST<!O0+MCEZ+B@(M#7V1FLYL^
MJ'MU&TV?^+6.V$%0,!#$+@D#4_?7Z:Z5&;1*O1E*5)'?B/UK=B=LK$%';8!=
MIX- 0,*]%^7%:*'>%_W\)F3G':'(2VL2&(W1-9B@.*/&,[1AU XM"[%3N&,?
MRF7KU$&%$0R>GDES'=EP$T8:=N1]11X=6X<5@\+R V',UPX]V_2[\ &FP\4N
M\&F %"4C4-^-C0HKH4?G49+SX* RNEP+T95:JZS /S>A$VQ$KZ/K-49:MH K
MV<\3&@#/=7R\.%W:%==_SR9I(2"*0 I&H:@*<E%1I;S25C4E9ZBD*!4476B+
M2J[X580@<GB+&5[(1)<-T@FM:*7:[@[:,7W=<OS0(^_&^1/P4YY*3N :F,!;
M7<</$%VG;2?4TF%D22D_+0T(!T@"&X].3Q P'_"NC0)H>9URDTN'#=%JO;$
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M2P$"% ,4    " !<@%Q3 I4TS78%  " /   %0              @ &' P
M<'1C="TR,#(Q,3 R.%]L86(N>&UL4$L! A0#%     @ 7(!<4P/X;T1T!
M@28  !4              ( !, D  '!T8W0M,C R,3$P,CA?<')E+GAM;%!+
M 0(4 Q0    ( %R 7%-_.KRCPS4  +/: @ <              "  =<-  !P
M=&-T+3(P,C$Q,#(X97@Y.3$T9&8S-C4N:'1M4$L! A0#%     @ 7(!<4_*X
M$Q3(%@  GK(  !0              ( !U$,  '!T8W0M,C R,3$P,CAX.&LN
9:'1M4$L%!@     %  4 40$  ,Y:      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
